COVID-19 associated with pulmonary mucormycosis; a case series

Ahmed, Okba F.; Al-Neaimy, Saoud; Kakamad, Fahmi H.; Ali, Razhan K.; Mikael, Tomas M.; Hamasaeed, Ahmed Gh; Mohammed, Shvan H.; Salih, Rawezh Q.; Salh, Abdulwahid M.; Hamasaeed, Muhammed Gh

doi:10.1016/j.amsu.2022.103434

Cited by 3 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent case report showed that a diabetic patient recovering from SARS-CoV-2 infection was followed by endobronchial necrosis as a result of pulmonary mucormycosis infection, which was confirmed by histopathological examinations and computed tomography [ 59 ]. Another study showed that four patients aged more than 42 years were administered with steroids, and half of them had comorbidities of pulmonary mucormycosis and SARS-CoV-2, in which computed tomography revealed pulmonary cavitation and empyema [ 60 ]. Patients with underlying comorbidities (diabetes and chronic kidney disease) may have a greater risk of fungal and bacterial infections.…”

Section: Mucormycosis and Sars-cov-2 Comorbiditymentioning

confidence: 99%

An Attention towards the Prophylactic and Therapeutic Options of Phytochemicals for SARS-CoV-2: A Molecular Insight

et al. 2023

View full text Add to dashboard Cite

The novel pathogenic virus was discovered in Wuhan, China (December 2019), and quickly spread throughout the world. Further analysis revealed that the pathogenic strain of virus was corona but it was distinct from other coronavirus strains, and thus it was renamed 2019-nCoV or SARS-CoV-2. This coronavirus shares many characteristics with other coronaviruses, including SARS-CoV and MERS-CoV. The clinical manifestations raised in the form of a cytokine storm trigger a complicated spectrum of pathophysiological changes that include cardiovascular, kidney, and liver problems. The lack of an effective treatment strategy has imposed a health and socio-economic burden. Even though the mortality rate of patients with this disease is lower, since it is judged to be the most contagious, it is considered more lethal. Globally, the researchers are continuously engaged to develop and identify possible preventive and therapeutic regimens for the management of disease. Notably, to combat SARS-CoV-2, various vaccine types have been developed and are currently being tested in clinical trials; these have also been used as a health emergency during a pandemic. Despite this, many old antiviral and other drugs (such as chloroquine/hydroxychloroquine, corticosteroids, and so on) are still used in various countries as emergency medicine. Plant-based products have been reported to be safe as alternative options for several infectious and non-infectious diseases, as many of them showed chemopreventive and chemotherapeutic effects in the case of tuberculosis, cancer, malaria, diabetes, cardiac problems, and others. Therefore, plant-derived products may play crucial roles in improving health for a variety of ailments by providing a variety of effective cures. Due to current therapeutic repurposing efforts against this newly discovered virus, we attempted to outline many plant-based compounds in this review to aid in the fight against SARS-CoV-2.

show abstract

Section: Mucormycosis and Sars-cov-2 Comorbiditymentioning

confidence: 99%

An Attention towards the Prophylactic and Therapeutic Options of Phytochemicals for SARS-CoV-2: A Molecular Insight

et al. 2023

View full text Add to dashboard Cite

show abstract

“…A total of 8727 cases of CAM are reported in the 88 qualified studies ( Table 1 ), the majority of them from India (n = 8388, 96.1%), 208 patients (2.4%) were from Egypt and 40 patients (0.46%) from Europe (France and Germany) ( Figure 2 ). CAM cases have also been reported in USA [ 41 ], Pakistan [ 70 ], Iran [ 84 ], Oman [ 113 ], Syria [ 115 ], Iraq [ 116 ], Latin America [ 117 ] and Turkey [ 7 ].…”

Section: Incidence Of Cammentioning

confidence: 99%

Clinical Phenotypes of COVID-19 Associated Mucormycosis (CAM): A Comprehensive Review

et al. 2022

View full text Add to dashboard Cite

A mucormycosis surge was reported during the COVID-19 pandemic in India. A literature search until 14 July 2022, with the aim of updating COVID-19-associated mucormycosis (CAM), identified 663 studies and 88 met inclusion criteria (8727 patients). India reported 8388 patients, Egypt 208 and Europe 40. Rhino-orbito-cerebral mucormycosis (ROCM) was identified among 8082 (98.3%) patients, followed by 98 (1.2%) with pulmonary. In India, 82.6% of patients had diabetes mellitus, with 82% receiving corticosteroids. In Europe, 75% presented pulmonary CAM, 32.5% had diabetes and 40% were immunocompromised. CAM was identified at a median of 17.4 days (IQR 7.5 days) post COVID-19 diagnosis, and PCR was performed in five studies. Rhino-orbital invasion is clinically obvious, while cerebral involvement presents with cavernous sinus thrombosis, meningitis and cerebrovascular disease. Symptoms of pulmonary CAM usually overlap with severe COVID-19 pneumonia. High-dose liposomal Amphotericin B (and early surgical debridement in ROCM) are the mainstay of therapy. The median mortality rate was estimated to be 21.4% (IQR 31.9%), increased by the presence of pulmonary (80% (IQR 50%) or cerebral involvement (50% (IQR 63.9%). In summary, different CAM clinical phenotypes need to be distinguished, influenced by geographical presentation. Opportunities exist for diagnosis and therapy optimization, based on earlier high-dose antifungal therapy, early source control, strict glycemic control and restriction of steroids to COVID-19 patients with oxygen requirements.

show abstract

Dexamethasone/methylprednisolone/remdesivir

2022

Reactions Weekly

View full text Add to dashboard Cite

COVID-19 associated with pulmonary mucormycosis; a case series

Cited by 3 publications

References 26 publications

An Attention towards the Prophylactic and Therapeutic Options of Phytochemicals for SARS-CoV-2: A Molecular Insight

An Attention towards the Prophylactic and Therapeutic Options of Phytochemicals for SARS-CoV-2: A Molecular Insight

Clinical Phenotypes of COVID-19 Associated Mucormycosis (CAM): A Comprehensive Review

Dexamethasone/methylprednisolone/remdesivir

Contact Info

Product

Resources

About